107 results about "Lungs metastasis" patented technology

The invention relates to the genetic engineering field, in particular to a human EpCAM targeted genetically engineered lymphocyte, a preparation method and use thereof. Technically, the invention aimsto provide a new effective means for immunotherapy of tumors. The technical scheme for solving the technical problem of the invention firstly provides a single-chain antibody capable of recognizing human EpCAM, a chimeric antigen receptor (CAR) containing the single-chain antibody, a vector carrying the chimeric antigen receptor, and a lymphocyte modified by the chimeric antigen receptor. After specific recognition of EpCAM overexpressed tumor cells, the EpCAM targeted chimeric antigen receptor modified lymphocyte provided by the invention can play an anti-tumor role through cytokine releaseand cytotoxicity, and can remarkably tumor formation, tumor growth and lung metastasis in vivo, thus having good application prospect.

Disclosed are micro / nano composite drug delivery compositions for use in diagnosis, prophylaxis, treatment and / or amelioration of one or more symptoms of a mammalian disease, disorder, dysfunction, or abnormal condition. In illustrative embodiments, pharmaceutical formulations comprising these composites are provided that are useful in methods for targeting selected mammalian cells and tissues, particularly human lung tissue, and delivering one or more therapeutic agents, particularly in the treatment of human lung cancers, such as melanoma lung metastases.

The invention discloses an Luc-GFP marked high-transitivity human hepatoma cell line. Hepatoma cells are taken as mother cells, a virus solution packaged with pCDH-CMV-Luc-EF1-GFP-Puro is transfectedthrough slow viruses, and then through puromycin screening, the high-transitivity human hepatoma cell line with stable GFP expression and luciferase activity is obtained. By using the Luc-GFP marked high-transitivity human hepatoma cell line, an in situ hepatoma model for a naked mouse is established through a cell suspension method and a tumor tissue block conversion method respectively, the tumor formation rate of the hepatoma model is 100% respectively, the rates of lung metastasis are 100% and 80% respectively, a foundation is laid for monitoring the growth of tumor in the level of livinganimals and evaluating the curative effect of hepatocellular carcinoma metastasis resistant medicine, and the cell line has greater application prospect.

The invention discloses albumin-loaded manganese dioxide and perflubron nanoparticles as well as a preparation method and application thereof, and relates to the technical field of biology, and the albumin-loaded manganese dioxide and perflubron nanoparticles are prepared from bovine serum albumin-loaded manganese dioxide and perflubron. The invention further provides a preparation method of the albumin-loaded manganese dioxide and perflubron nanoparticle and application of the albumin-loaded manganese dioxide and perflubron nanoparticle in tumor bimodal imaging and enhancement of high-intensity focused ultrasound tumor immunogenic death. The invention has the advantages that the albumin-loaded manganese dioxide and perflubron nanoparticles obtained by the preparation method have the characteristics of enhancing high-intensity focused ultrasound immune death and biocompatibility and being high in active targeting enrichment amount in tumors, and tumor diagnosis and real-time monitoringcan be realized through CT and MRI bimodal imaging; by enhancing high-intensity focused ultrasound tumor immunogenic death, tumor growth and lung metastasis can be inhibited in vivo, and the survivalrate of animals can be increased.

The invention discloses a fusion gene line RAB22A-NoeFs for diagnosing and / or treating osteosarcoma. The first and second exons of the RAB22A gene are fused with the 54408036th to 54476718th positionof chromosome 20 after being inversed, the fusion gene line includes the following six fusion genes: RAB22A-NoeF1, RAB22A-NoeF2, RAB22A-NoeF3, RAB22A-NoeF4, RAB22A-NoeF5 and RAB22A-NoeF6, and the nucleotide sequences of the fusion genes are sequentially represented by SEQ ID NO:1-6. The six fusion genes of the fusion gene line RAB22A-NoeFs can promote the migration and invasion of osteosarcoma cells, wherein the RAB22A-NoeF1 has above functions, and also can promote the lung metastasis of the osteosarcoma cells. The fusion gene line RAB22A-NoeFs can be used as a specific therapeutic target forosteosarcoma, and has a great application prospect.

The invention discloses a chemotherapy-immunotherapy combined drug and a preparation method and application thereof. A PTX micelle based on PEG-P (CL-DTC) is designed, and the technical effect of combination of the PTX micelle and vesicles (CPs-CDN) with asymmetric membrane structures of interferon-gene-carrying stimulating protein (STING) pathway agonist Cyclic Dinucleotide (CDN) in treatment of breast cancer (TNBC) is studied. The PTX micelle is simple in preparation method, small in particle size and high in drug loading capacity and has good stability and reduction responsiveness. Experiments show that after the PTX micelle is combined with the CPs-CDN, more BMDC maturation can be promoted, CD4<+> T and CD8<+> T cells in tumors and spleens are significantly increased, inhibitory Treg is reduced, tumor growth and lung metastasis are obviously inhibited, the lifetime of mice is prolonged, and the advantages of chemotherapy-immunotherapy are embodied.

The invention provides a method for inducing adult liver stem cells for transforming to high metastatic liver cancer cells and the stable liver cancer cells screened by the method. The method comprises the following steps: S1: performing amplification, culture and preservation of mice adult liver stem cells; S2: employing a gene transfection technology for transferring a lentiviral vector containing the Notch1 gene into the mice adult liver stem cells to obtain the mice adult liver stem cells for stable over-expression of the Notch1; S3: using the mice adult liver stem cells for stable over-expression of Notch1, employing a selective condition culture method for culture, performing in-vitro further differentiation, screening the liver cancer cells having strong and stable tumorigenic capability; and S4: employing the screened liver cancer cells, through an in-situ liver transplantation tumor model having same species, liver cancer is formed on liver, double-lung metastasis tumor is spontaneously formed, so that the high metastatic liver cancer cells can be obtained. The screened stable liver cancer cells by the method of the invention have the advantages of short tumor formation time and good tumorigenicity, and have lung metastasis capability.

The invention discloses a living cell drug delivery system based on macrophages, and a preparation method and application thereof. The living cell drug delivery system based on macrophages comprises macrophages, anchored chemotherapeutic drugs and anchored cell lysis-promoting groups. The preparation method comprises the following steps: taking mouse bone marrow cells, culturing in vitro, adding arecombinant mouse macrophage colony stimulating factor and a mouse breast cancer 4T1 cell culture supernatant or lipopolysaccharide LPS into a culture medium, continuously culturing, and inducing macrophage polarization to obtain regulatory M1 or M2 macrophages; and jointly incubating the anchored chemotherapeutic drug and the anchored cell lysis-promoting group in the macrophage culture medium to prepare the macrophage-based living cell drug delivery system. The prepared living cell drug delivery system based on macrophages can be actively targeted to the lung metastasis focus of breast cancer, and lung metastasis of breast cancer is effectively inhibited.

The invention relates to a use of an miR-100 inhibitor in cancer metastasis reduction, and concretely relates to a use of a reagent for determining the miR-100 expression level in the preparation of breast cancer diagnosis reagents, and a use of the miR-100 inhibitor, and a use of the miR-100 inhibitor or an miR-100 antagonist in the preparation of medicines for treating breast cancer. Up-regulation of miR-100 in in-vivo tumor related macrophages and in-vitro induced M2 type macrophages is induced by tumor micro-environment. In in-vivo test, the microRNA antagonist knocks down the expression of the miR-100 in mouse mammary gland tumor tissues, and a case that in-situ tumor growth has no statistic difference, the quantity of lung metastasis tubercles is obviously down-regulated and the mammary gland tumor metastasis is inhibited in an experiment group of the miR-100 down-regulation in the tumor related macrophages is found.

The invention discloses an application of a polypeptide Kp-10 in preparation of a medicine for treating and preventing osteosarcoma. The amino acid sequence of the polypeptide Kp-10 is DSSDSSDSSDSSDSSDSSYNWNSFGLRF. Researches find that expression of GPR54 / KiSS-1 in osteosarcoma tissues is obviously lower than that in normal tissues beside the tumor tissues, and is highly related to clinical prognosis, and the polypeptide Kp-10 and a receptor GPR54 of the polypeptide Kp-10 can inhibit proliferation and migration capacity and lung metastasis capacity of osteosarcoma cells, so that the polypeptide Kp-10 can be used for preparing medicines for treating and preventing osteosarcoma, and a new thought is provided for exploration of osteosarcoma targeted medicine.

The invention relates to a 4-aminopyrrolopyrimidine derivative and a preparation method and application thereof, and belongs to the field of medicines. The invention provides a compound shown as a formula I or pharmaceutically acceptable salt thereof. The compound can significantly inhibit the activity of RIPK1 kinase, has high selectivity and good safety, and is a potential therapeutic drug for RIPK1 kinase related diseases. TNF alpha induced SIRS model and mouse melanoma lung metastasis model experiments prove that the compound disclosed by the invention can play a role in inhibiting RIPK1 kinase in vivo and has remarkable anti-inflammatory and anti-tumor metastasis activity. The invention provides a new strategy and means for comprehensively treating tumor metastasis.

The invention discloses applications of a compound traditional Chinese medicinal composition in preparing medicines for inhibiting skin melanoma lung metastasis. The compound traditional Chinese medicinal composition is prepared from the following components in parts by weight: 15-30 parts of radix astragali preparata, 15-30 parts of stir-baked radix codonops, 10-20 parts of stir-baked white atractylodes rhizome, 15-30 parts of poria cocos, 15-30 parts of rhizoma dioscoreae, 5-10 parts of radix glycyrrhizae preparata, 10-20 parts of smoked plum preparata, 10-20 parts of rhizoma sparganii, 10-20 parts of rhizoma curcumae, 15-30 parts of herba agrimoniae, and 15-30 parts of herba patriniae. The compound traditional Chinese medicinal composition provided by the invention can obviously inhibit the skin melanoma lung metastasis under the condition that the body immunity is not reduced, and meanwhile, the medicine is low in preparation cost, and easy to popularize and apply.

The invention belongs to the technical field of medical products, and discloses an application to promotion of squamous cell carcinoma metastasis based on DDX19A. In function, DDX19A is found to promote in-vitro migration and invasion of cervical squamous cell carcinoma cells and in-vivo lung metastasis. In terms of mechanism, overexpression of the DDX19A increases NOX1 expression, increases production of reactive oxygen species (ROS), and induces migration and invasion of the cervical squamous cell carcinoma cells. Rescue experiments show that overexpression of NOX1 can retrieve and knock down cervical cancer squamous cell carcinoma cell invasion and migration and ROS generation caused by DDX19A, and the inventor further discovers that an ROS inhibitor N-acetylcysteine can inhibit DDX19A-induced cervical squamous cell carcinoma cell invasion and migration. Therefore, the DDX19A is proved to promote metastasis of the cervical squamous cell carcinoma by inducing NOX1 to mediate ROS production. Blocking of a DDX19A / NOX1 / ROS axis can be a potential therapeutic target for patients with cervical squamous cell carcinoma.

The invention provides a preparation method for a liver-restoring tablet. The liver-restoring tablet is prepared from the bulk drugs consisting of 800 g of isatis root, 166 g of oriental wormwood, 266 g of curcuma tuber, 266 g of Chinese magnoliavine, 266 g of licorice, 133 g of Chinese angelica, 400 g of milk vetch and 200 g of acanthopanax root through supercritical extraction. With the preparation method, the content of the bulk drugs in the liver-restoring tablet is greatly increased, and the dose of the tablet is reduced. The invention further provides application of the liver-restoring tablet in preparation of drugs used for inhibiting cell proliferation of the mouse melanoma lung metastasis strain B16-F10.

The invention belongs to the field of compounds and relates to the use of compound NZ001 in liver cancer metastasis. The present invention proves through in vitro and in vivo experiments that the compound NZ001 (C34H30F2N4O6S) can inhibit the proliferation of highly metastatic liver cancer cells, promote apoptosis and inhibit cycle, inhibit tumor angiogenesis, and inhibit intrapulmonary metastasis and intrahepatic dissemination of tumors. The present invention has been tested, and the results have confirmed the important role of simultaneous inhibition of MET and VEGFR2 signaling pathways in the treatment of liver cancer metastasis, and provide new targets and ideas for clinical treatment of liver cancer metastasis.

The present invention relates to the use of probucol or derivatives thereof for preparing drugs for inhibiting tumour metastasis, preferably breast cancer metastasis, and more preferably lung metastasis of breast cancer. The present invention also relates to the use of a pharmaceutical composition of probucol for preparing drugs for inhibiting tumour metastasis, preferably breast cancer metastasis, and more preferably lung metastasis of breast cancer, wherein the pharmaceutical composition of probucol comprises a therapeutically effective amount of one or more compounds selected from probucol or derivatives thereof, and pharmaceutical excipients.

The invention relates to the technical field of medical bioengineering, in particular to an anti-human YKL-40 neutralizing monoclonal antibody. The amino acid sequence of a heavy chain variable regionof the monoclonal antibody is shown as SEQ ID NO:1, and the amino acid sequence of a light chain variable region of the monoclonal antibody is shown as SEQ ID NO:2. According to the invention, uniquesequence information of the monoclonal antibody is provided, and a hybridoma cell strain secreting the monoclonal antibody and application of the monoclonal antibody and the hybridoma cell strain inpreparation of drugs for inhibiting lung metastasis of liver cancer are also provided.

The invention discloses the application of an inhibitor GSK-J4 of histone demethylase to preparation of a therapeutic drug for osteosarcoma. That histone deemthylase KDM5B is associated with the treatment of the osteosarcoma is proved for the first time. GSK-J4 acts on the histone demethylase KDM5B to significantly inhibit proliferation of osteosarcoma cells, and therefore, can be used as a new breakthrough for preparing a drug for treating the osteosarcoma. Besides, the invention also discloses the ability of the GSK-J4 for inhibiting transfer of the osteosarcoma cells by targeting the KDM5Bfor the first time, and provides a novel idea for researching and developing a drug for treating lung metastasis and osseous metastasis of the osteosarcoma.

The invention relates to a tumor treatment method for patients with terminal malignant tumor lung metastasis with malignant pleural effusion. The method includes the steps: draining and collecting pleural effusion from cancerous hydrothorax appearing in a patient with lung metastasis, centrifuging and enriching, then separating out metastatic pleural effusion mononuclear cells (PEMC), adjusting the concentration of 5*10<5> / ml in pores of a 24-pore plate, placing in an incubator, amplifying the PEMC with combined application of peripheral blood mononuclear cells (PBMC) in healthy adults after irradiation with IL-2, and taking the PBMC after irradiation as trophocytes to stimulate the amplification and cytotoxicity tests of the PEMC. The invention also provides a use of the PEMC prepared bythe method in preparation of drugs for treating terminal malignant tumor lung metastasis with malignant pleural effusion. The advantages show that provided is a PEMC amplification method with higher efficiency and relatively convenient technology, the amplification efficiency reaches 1000 times, and high cytotoxicity killing effect is achieved.

The invention discloses application of hsa_circ_0007444 in preparation of a medicine for treating ovarian cancer. According to the research, a hsa_circ_0007444 overexpression plasmid vector is prepared, and the function of the hsa_circ_0007444 overexpression plasmid vector in ovarian cancer cells is verified by overexpression lentivirus and specific siRNA. The overexpression hsa_circ_0007444 can obviously inhibit proliferation, invasion and migration of ovarian cancer and promote apoptosis of ovarian cancer, and knockdown of hsa_circ_0007444 can obviously promote proliferation, invasion and migration of ovarian cancer and inhibit apoptosis of ovarian cancer. Meanwhile, hsa_circ_0007444 overexpression can inhibit growth and lung metastasis of ovarian cancer in vivo and is an important target for treating ovarian cancer.

The invention relates to a high metastasis human breast carcinoma cell subline MDA-MB-231sci, which has biological and pathological features and special metastasis phenotypes. The biological features are as follows: the MDA-MB-231sci cells are typical polygonal epithelioid cells, have rich cytoplasm and big and round karyon, grow adherent to the wall with almost uniform size and are closely arranged with clear boundary. The pathological features are as follows: a tumor cell of a nude mouse in vivo metastasis part has the similar structure with the subcutaneous tumor cell, short metastasis time and high metastasis rate, wherein the metastasis time is shortened to 26-42 days; a lung metastasis rate is 100%, meanwhile, a part of axillary lymph node metastasis of an animal is performed. An establishing method for the high metastasis human breast carcinoma cell line comprises the following steps of: (1) establishing a human breast carcinoma orthotopic transplantation tumor model; (2) sieving an orthotopic transplantation lung targeted metastasis model; and (3) establishing and passaging a human breast and lung carcinomas targeted high metastasis cell line. In the invention, the success rate is improved by sieving surgical excision tumor of each generation in vivo and corresponding breast.

The invention relates to the field of pharmaceutical preparations, and relates to a calcium phosphate-lipid nano-drug co-delivery system consisting of low molecular weight heparin and a prodrug of a natural drug and a preparation method for the nano-drug co-delivery system. According to the nano-drug co-delivery system, nanoparticles prepared from a biodegradable lipid material are taken as carriers, and the phosphorylated prodrug PIC-POOH of the natural drug piceatannol (PIC) is physically entrapped, and the low molecular weight heparin (LMWH) adsorbs on the outer layers of the carriers by static electricity; and a nano preparation concentrates at a tumor site by utilizing the long circulating performance of the nano preparation and the enhanced permeability and retention (EPR) effect ofa solid tumor tissue, a related pathway for tumor cell metastasis is then regulated, angiogenesis is inhibited, and the anti-tumor metastasis action is exerted. Proved by assays, the nano-drug co-delivery system can inhibit the epithelial-mesenchymal transition (EMT) progress of tumor cells; proved by a tube formation assay, the nano-drug co-delivery system can significantly inhibit tumor angiogenesis; proved by in vivo administration evaluation, the nano-drug co-delivery system can reduce formation of lung metastasis on a mice model, and prolongs the survival time of tumor-bearing mice; and the nano-drug co-delivery system has an obvious anti-tumor metastasis effect, especially reduces triple negative breast cancer metastasis, and has high safety.

The invention belongs to the field of medicines, and particularly relates to use of active substances such as an antibody protein, a nucleic acid sequence and a small molecule inhibitor for reducing the activity or expression quantity of CXCL13 protein in preparing medicines for treating malignant tumor metastasis. The technical problem to be solved is to provide a targeted therapeutic solution for immunoregulatory molecules of B cells. The targeted therapeutic solution is to provide the use of the active substances for reducing the activity or expression quantity of the CXCL13 protein in preparing the medicines for treating the malignant tumor metastasis. Experiments show that a CXCL13 blocking agent or blocking antibody can significantly inhibit the lung metastasis of malignant tumors; and by combination of the CXCL13 blocking agent or blocking antibody with chemotherapeutics or T cell immune negative regulators, the inhibition on the lung metastasis of the malignant tumors is particularly effective, and a better synergic effect can be obtained. A new and effective choice for the treatment of the malignant tumor metastasis is provided.

The invention discloses a Hotair small-molecule inhibitor and application thereof in preparation of tumor treating drugs and belongs to the field of pharmaceutical preparations containing organic effective ingredients. The chemical name of the Hotair small-molecule inhibitor is 7-nitrogen-2-[4-(7-nitrogen-3-oxy-4,9-dihydrofuran[3,2-b]quinoxaline-2-yl)phenyl]-4,9-dihydrofuran[3,2-b]quinoxaline-3-ketone, and the molecular weight is 540. The Hotair small-molecule inhibitor can specifically inhibit binding between the 5' end of Hotair and EZH2 protein in PRC2, effectively inhibit EZH2 nucleus entry in U87 cells, and effectively inhibits growth and lung metastasis of a breast cancer tumor model in an in-vivo experiment of a rat. The Hotair small-molecule inhibitor can be applied to the preparation of the tumor treating drugs, has a great clinical significance on tumor occurrence, development and treatment and has broad application prospects.

The invention provides a plaster for treating fractures, the active ingredients contained in it are prepared from the following raw materials in parts by weight: 20-28 parts of red chopsticks, 15-20 parts of hair stachys, 18-22 parts of wild mat grass 10-20 parts of Lingxiang Artemisia, 10-20 parts of Angelica sinensis, the plaster has the effect of treating fractures, and can inhibit the proliferation of B16-F10 cells of mouse melanoma lung metastases.

The present invention relates to a LOX-GFP marker and methods of analyzing tumor burden in ascites or in lung. The invention also relates to a new LOX-GFP-LM cell line which demonstrates increased lung metastasis. The methods of the invention result in better quantitative tumor burden assessment and improved efficacy evaluation. These improved models provide a feasible alternative for ascites or experimental metastasis evaluation of novel cancer therapeutics.

The present invention relates to a method and composition for treating melanoma, aggressive / invasive melanoma, metastatic melanoma or melanoma resistant. More particularly, inventors have shown that high expression of PTX3 correlates with melanoma invasiveness and with a poorer survival rate in metastatic melanoma patients. PTX3 knockdown inhibited melanoma cell migration, invasion, lung metastasis, and NFκB signaling pathway. An addition of melanoma-derived or recombinant PTX3, or overexpression of PTX3 enhanced motility of low migratory cells. Finally, they found that TLR4 and MYD88 knockdown or targeting inhibited PTX3-induced melanoma cell migration, suggesting that PTX3 functions through a TLR4 / NFκB-dependent pathway. Accordingly, the invention relates to a method for predicting the survival time of a subject suffering from melanoma, aggressive / invasive melanoma, metastatic melanoma or melanoma resistant by quantifying the expression level of PTX3 in a biological sample and to a method of treating melanoma, aggressive / invasive melanoma, metastatic melanoma or melanoma resistant by using the inhibitors of PTX3.

The invention provides a pentamethine-cyanine-dye photosensitive dye with a long lifetime of excited state and a preparation method and application thereof. The photosensitive dye has a structure shown in a general formula I. The pentamethine-cyanine-dye photosensitive dye with long lifetime of excited state can have relatively high singlet oxygen quantum yield and relatively long lifetime of excited state. Under the excitation of near-infrared light, the photodynamic killing can be carried out on normoxic and hypoxic cancer cells. Meanwhile, the pentamethine-cyanine-dye photosensitive dye with a long lifetime of excited state possesses a good application prospect in the aspects of treating solid tumors in vivo and inhibiting lung metastasis of cancer cells.

The present invention relates to IL-8 inhibitor compounds, preferably dual CXCR1 / CXCR2 receptor inhibitors, useful in the treatment and / or prevention of some sarcomas, preferably in the treatment and / or prevention of osteosarcoma, Ewing sarcoma, rhabdomyosarcoma or lung metastasis associated thereof.

The invention relates to an allicin-entrapped cell microparticle drug delivery system as well as a preparation method and application thereof, traditional Chinese medicine garlic active ingredient organic sulfide is loaded into tumor cell microparticles, and the drug delivery microparticles have biocompatibility, higher metastatic focus organ targeting and better tumor metastasis resistance. The invention also relates to a preparation method of the drug delivery system and application of the drug delivery system in preparation of anti-tumor metastasis drugs. The organ-targeted allicin drug-containing cell microparticles obtained according to the preparation method provided by the invention have a remarkable inhibition effect on melanoma lung metastasis, Lewis lung cancer lung metastasis and other tumor metastasis, and the allicin-entrapped cell microparticle drug delivery system is a traditional Chinese medicine anti-tumor metastasis drug delivery system with biocompatibility for accurately targeting metastatic lesion organs.